Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore suitable as vaccine basis. Here we present results from a clinical study in which patients with malignant melanoma (MM) with verified progressive disease received vaccination with autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) or with autologous/allogeneic tumor lysate (HLA-A2(-) patients) in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Cytotherapy |
Vol/bind | 12 |
Udgave nummer | 6 |
Sider (fra-til) | 721-34 |
Antal sider | 14 |
ISSN | 1465-3249 |
DOI | |
Status | Udgivet - 1 okt. 2010 |
ID: 32304621